WO2001088159A3 - Cd28 synthebody for the modulation of immune responses - Google Patents
Cd28 synthebody for the modulation of immune responses Download PDFInfo
- Publication number
- WO2001088159A3 WO2001088159A3 PCT/US2001/015707 US0115707W WO0188159A3 WO 2001088159 A3 WO2001088159 A3 WO 2001088159A3 US 0115707 W US0115707 W US 0115707W WO 0188159 A3 WO0188159 A3 WO 0188159A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variants
- binding
- cdr
- binding sequence
- synthebody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001261628A AU2001261628A1 (en) | 2000-05-16 | 2001-05-16 | Cd28 synthebody for the modulation of immune responses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20448300P | 2000-05-16 | 2000-05-16 | |
US60/204,483 | 2000-05-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001088159A2 WO2001088159A2 (en) | 2001-11-22 |
WO2001088159A3 true WO2001088159A3 (en) | 2002-04-11 |
Family
ID=22758081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/015707 WO2001088159A2 (en) | 2000-05-16 | 2001-05-16 | Cd28 synthebody for the modulation of immune responses |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001261628A1 (en) |
WO (1) | WO2001088159A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10240418A1 (en) * | 2002-09-02 | 2004-03-11 | Avontec Gmbh | Formulation for introducing nucleic acids into eukaryotic cells |
WO2005021595A1 (en) * | 2003-08-28 | 2005-03-10 | Euro-Celtique S.A. | Methods of antibody engineering using antibody display rules |
PL1752471T3 (en) | 2005-01-05 | 2009-04-30 | F Star Biotechnologische Forschungs Und Entw M B H | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
KR20170091801A (en) | 2008-10-02 | 2017-08-09 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | CD86 Antagonist Multi-Target Binding Proteins |
JP5856065B2 (en) | 2009-11-30 | 2016-02-09 | ジェネンテック, インコーポレイテッド | Compositions and methods for tumor diagnosis and treatment |
WO2013092723A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022377A1 (en) * | 1995-01-19 | 1996-07-25 | Armitage, Ian, M. | Activation of t-cells by modified, antigenic immunoglobulins |
WO1999025378A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Immunoglobulin molecules having a synthetic variable region and modified specificity |
WO1999029344A1 (en) * | 1994-09-19 | 1999-06-17 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
-
2001
- 2001-05-16 WO PCT/US2001/015707 patent/WO2001088159A2/en active Application Filing
- 2001-05-16 AU AU2001261628A patent/AU2001261628A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029344A1 (en) * | 1994-09-19 | 1999-06-17 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
WO1996022377A1 (en) * | 1995-01-19 | 1996-07-25 | Armitage, Ian, M. | Activation of t-cells by modified, antigenic immunoglobulins |
WO1999025378A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Immunoglobulin molecules having a synthetic variable region and modified specificity |
Non-Patent Citations (4)
Title |
---|
"Peptides for the new millennium", 2000, KLUWER ACADEMIC PUBL., DORDRECHT, THE NETHERLANDS, XP001031358 * |
A. TRUNEH ET AL.: "Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): Analysis by site-directed mutagenesis.", MOLECULAR IMMUNOLOGY, vol. 33, no. 3, February 1996 (1996-02-01), Oxford, GB, pages 321 - 334, XP001031316 * |
H. ZAGHOUANI ET AL.: "Engineered immunoglobulin molecules as vehicles for T cell epitopes.", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 10, no. 2-3, 1993, Switzerland, pages 265 - 278, XP002177699 * |
J. COOK ET AL.: "Recombinant antibodies containing an engineered B-cell epitope capable of eliciting conformation-specific antibody responses.", VACCINE, vol. 13, no. 18, December 1995 (1995-12-01), Guildford, GB, pages 1770 - 1778, XP004057383 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Also Published As
Publication number | Publication date |
---|---|
AU2001261628A1 (en) | 2001-11-26 |
WO2001088159A2 (en) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001088159A3 (en) | Cd28 synthebody for the modulation of immune responses | |
WO2002083738A1 (en) | Cyclic single strand trispecific antibody | |
WO2001012804A3 (en) | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES | |
DE60109916D1 (en) | MODULATION OF OLIGONUCLEOTIDE CPG-MEDIATED IMMUNOSTIMULATION BY MODIFICATION OF NUCLEOSIDES | |
WO2002062850A3 (en) | Hybrid antibodies and uses thereof | |
WO1999006544A8 (en) | Membrane-bound cytokine compositions and methods of modulating an immune response using same | |
IL145813A0 (en) | SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ1 | |
HK1048126A1 (en) | Soluble ctla4 mutant molecules and uses thereof. | |
NO20012033D0 (en) | Polyurethane prepolymers having alkoxysilane end groups, process for their preparation, their use in the preparation of sealants | |
DE60235553D1 (en) | ANTIGENBINDING DOMAIN FROM FISH | |
DK1117672T3 (en) | Antisense modulation of survivin expression | |
WO2021173896A8 (en) | Materials and methods for modulating an immune response | |
WO1995006735A3 (en) | Nucleotide sequences for novel protein tyrosine phosphatases | |
WO2002040668A3 (en) | Proteins and dna sequences underlying these proteins used for treating inflammations | |
WO2002083910A3 (en) | Sequence specific recombinase-based methods for producing intron containing vectors and compositions for use in practicing the same | |
ATE323166T1 (en) | FRAGMENTS OF INTRON A OF CITOMEGALOVIRUS | |
DE69831951D1 (en) | PSEUDOMONAS EXOTOXIN-A-SIMILAR CHIMERIC IMMUNOGENES | |
WO2003057843A8 (en) | Methods and materials for modulating trpc4 | |
NZ500151A (en) | A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence | |
GB2375112A (en) | Combinatorial protein domains | |
DE69334156D1 (en) | Method for reducing the immunogenicity of variable regions of antibodies | |
DE69836024D1 (en) | PSEUDOMONAS EXOTOXIN A-SIMILAR CHIMERIC IMMUNOGENES FOR TRIGGERING A SECRETARY IGA-MEDIATED IMMUNE RESPONSE | |
EP1908835A3 (en) | Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches | |
WO2002002632A3 (en) | Modulation of tetraspanin function | |
EP0369567A3 (en) | Chimeric antibodies directed against metal chelates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |